Advertisement

ADVERTISEMENT

Hina M. Porcelli

News
FDA Approves Dostarlimab-gxly for Adults With dMMR Endometrial Cancer
04/22/2021
The FDA has approved dostarlimab-gxly for the treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed during or after a platinum-containing therapy.
The FDA has approved dostarlimab-gxly for the treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed during or after a platinum-containing therapy.
The FDA has approved...
04/22/2021
Oncology
Conference Coverage
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma: ECHELON-1
06/04/2022
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a 41% reduction in the risk of death over doxorubicin, bleomycin, vinblastine, and dacarbazine for previously untreated classical Hodgkin lymphoma, according to an...
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a 41% reduction in the risk of death over doxorubicin, bleomycin, vinblastine, and dacarbazine for previously untreated classical Hodgkin lymphoma, according to an...
Brentuximab vedotin plus...
06/04/2022
Oncology
Conference Coverage
Trabectedin Does Not Improve Survival vs Standard Chemotherapy for BRCA–Positive Ovarian Cancer
06/06/2022
Single-agent trabectedin was not associated with improved survival outcomes compared to standard chemotherapy for patients with BRCA–positive ovarian cancer, according to results from a phase 3 trial.
Single-agent trabectedin was not associated with improved survival outcomes compared to standard chemotherapy for patients with BRCA–positive ovarian cancer, according to results from a phase 3 trial.
Single-agent trabectedin was not...
06/06/2022
Oncology
Conference Coverage
First-Line Rucaparib Maintenance Following Chemotherapy Provides Significant Benefit in Ovarian Cancer
06/06/2022
Rucaparib monotherapy provides significant benefit over placebo as first-line maintenance treatment following platinum-based chemotherapy in ovarian cancer, according to results from the ATHENA-MONO trial.
Rucaparib monotherapy provides significant benefit over placebo as first-line maintenance treatment following platinum-based chemotherapy in ovarian cancer, according to results from the ATHENA-MONO trial.
Rucaparib monotherapy provides...
06/06/2022
Oncology
Conference Coverage
Addition of Relacorilant to Nab-Paclitaxel Improves OS in Recurrent Platinum–Resistant Ovarian Cancer
06/06/2022
OS data from a phase 2 clinical trial confirm the benefit of adding intermittent relacorilant to nab-paclitaxel for patients with ovarian cancer, especially those without primary platinum-refractory disease.
OS data from a phase 2 clinical trial confirm the benefit of adding intermittent relacorilant to nab-paclitaxel for patients with ovarian cancer, especially those without primary platinum-refractory disease.
OS data from a phase 2 clinical...
06/06/2022
Oncology
News
Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status
06/28/2022
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic...
06/28/2022
Oncology
Conference Coverage
First-Line Ibrutinib Combined With Bendamustine-Rituximab and Rituximab Maintenance Improves PFS in MCL
06/04/2022
Ibrutinib combined with bendamustine plus rituximab and rituximab maintenance significantly improved PFS vs standard chemoimmunotherapy in patients aged ≥65 years with untreated MCL, according to findings from the phase 3 SHINE trial.
Ibrutinib combined with bendamustine plus rituximab and rituximab maintenance significantly improved PFS vs standard chemoimmunotherapy in patients aged ≥65 years with untreated MCL, according to findings from the phase 3 SHINE trial.
Ibrutinib combined with...
06/04/2022
Oncology
Conference Coverage
Brentuximab Vedotin Improves EFS in Pediatric Patients With High–Risk Hodgkin Lymphoma
06/04/2022
Brentuximab vedotin added to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVE-PC) improves EFS over AVE-PC plus bleomycin in pediatric patients with previously untreated, high–risk Hodgkin lymphoma.
Brentuximab vedotin added to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVE-PC) improves EFS over AVE-PC plus bleomycin in pediatric patients with previously untreated, high–risk Hodgkin lymphoma.
Brentuximab vedotin added to...
06/04/2022
Oncology
Conference Coverage
Experts Observe Durable Antitumor Activity With Selpercatinib for RET Fusion-Positive Solid Tumors
06/28/2022
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to...
06/28/2022
Oncology
Conference Insider
Venetoclax–Azacitidine Improves OS Over Azacitidine Alone in Treatment-Naïve Patients With tMN, A-MDS/MPNs
06/23/2021
According to data presented at ASCO 2021, venetoclax plus azacitidine improved survival over azacitidine alone in treatment-naïve patients with tMN and antecedent MDS or MPNs.
According to data presented at ASCO 2021, venetoclax plus azacitidine improved survival over azacitidine alone in treatment-naïve patients with tMN and antecedent MDS or MPNs.
According to data presented at...
06/23/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use